Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions

被引:118
作者
Gervois, N
Guilloux, Y
Diez, E
Jotereau, F
机构
[1] INSERM,U211,F-44035 NANTES,FRANCE
[2] FAC SCI NANTES,F-44035 NANTES,FRANCE
关键词
D O I
10.1084/jem.183.5.2403
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Coculture of melanoma cells and T cell clones derived from tumor-infiltrating lymphocytes (TIL) generally results in lysis of the antigen-bearing tumor cells but to inefficient proliferation and IL-2. secretion by responder T cells. This suboptimal activation is classically explained by an inability of tumor cells to provide costimulatory signals. Here we analyzed the responses to synthetic peptides of HLA-A2.1-restricted CTL clones specific for melanoma antigens MART-1 and NA17-A. We showed that peptide concentrations ranging from 1 pM to 10 nM efficiently sensitized the peptide transporter-deficient T2 cells to lysis. T2 cells pulsed with melanoma peptides also induced TIL proliferation and detectable secretion of IL-2, IFN-gamma and GM-CSF, but only for peptide concentrations 10- to 10,000-fold higher than those required for lysis. Hence this suggests that partial triggering of TIL clones by melanoma cells could be due to expression of appropriate MHC-peptide complexes at subthreshold levels. In support of this, we showed that melanoma cells, unable to trigger IL-2 secretion, developed this ability when incubated with the appropriate peptide. These results indicate that the level of antigens expressed on melanoma tumors critically affects TIL activation status and thus, the efficiency of specific immune reactions mediated by these cells.
引用
收藏
页码:2403 / 2407
页数:5
相关论文
共 15 条
[1]  
Atherton E., 1981, J CHEM SOC P1, V1, P538
[2]   NEW PERSPECTIVES OF CD28-B7-MEDIATED T-CELL COSTIMULATION [J].
BLUESTONE, JA .
IMMUNITY, 1995, 2 (06) :555-559
[3]   FROM DEFINED HUMAN TUMOR-ANTIGENS TO EFFECTIVE IMMUNIZATION [J].
BOON, T ;
GAJEWSKI, TF ;
COULIE, PG .
IMMUNOLOGY TODAY, 1995, 16 (07) :334-336
[4]   A NEW GENE CODING FOR A DIFFERENTIATION ANTIGEN RECOGNIZED BY AUTOLOGOUS CYTOLYTIC T-LYMPHOCYTES ON HLA-A2 MELANOMAS [J].
COULIE, PG ;
BRICHARD, V ;
VANPEL, A ;
WOLFEL, T ;
SCHNEIDER, J ;
TRAVERSARI, C ;
MATTEI, S ;
DEPLAEN, E ;
LURQUIN, C ;
SZIKORA, JP ;
RENAULD, JC ;
BOON, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :35-42
[5]   A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene [J].
Guilloux, Y ;
Lucas, S ;
Brichard, VG ;
VanPel, A ;
Viret, C ;
DePlaen, E ;
Brasseur, F ;
Lethe, B ;
Jotereau, F ;
Boon, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :1173-1183
[6]   DEFECTIVE LYMPHOKINE PRODUCTION BY MOST CD8+ AND CD4+ TUMOR-SPECIFIC T-CELL CLONES DERIVED FROM HUMAN MELANOMA-INFILTRATING LYMPHOCYTES IN RESPONSE TO AUTOLOGOUS TUMOR-CELLS IN-VITRO [J].
GUILLOUX, Y ;
VIRET, C ;
GERVOIS, N ;
LEDREAN, E ;
PANDOLFINO, MC ;
DIEZ, E ;
JOTEREAU, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (09) :1966-1973
[7]   THE B7 AND CD28 RECEPTOR FAMILIES [J].
JUNE, CH ;
BLUESTONE, JA ;
NADLER, LM ;
THOMPSON, CB .
IMMUNOLOGY TODAY, 1994, 15 (07) :321-331
[8]   IDENTIFICATION OF THE IMMUNODOMINANT PEPTIDES OF THE MART-1 HUMAN-MELANOMA ANTIGEN RECOGNIZED BY THE MAJORITY OF HLA-A2-RESTRICTED TUMOR-INFILTRATING LYMPHOCYTES [J].
KAWAKAMI, Y ;
ELIYAHU, S ;
SAKAGUCHI, K ;
ROBBINS, PF ;
RIVOLTINI, L ;
YANNELLI, JR ;
APPELLA, E ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :347-352
[9]   CLONING OF THE GENE CODING FOR A SHARED HUMAN-MELANOMA ANTIGEN RECOGNIZED BY AUTOLOGOUS T-CELLS INFILTRATING INTO TUMOR [J].
KAWAKAMI, Y ;
ELIYAHU, S ;
DELGADO, CH ;
ROBBINS, PF ;
RIVOLTINI, L ;
TOPALIAN, SL ;
MIKI, T ;
ROSENBERG, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3515-3519
[10]   SPECIFICITY, T-CELL RECEPTOR DIVERSITY AND ACTIVATION REQUIREMENTS OF CD4+ AND CD8+ CLONES DERIVED FROM HUMAN MELANOMA-INFILTRATING LYMPHOCYTES [J].
PANDOLFINO, MC ;
VIRET, C ;
GERVOIS, N ;
GUILLOUX, Y ;
DAVODEAU, F ;
DIEZ, E ;
JOTEREAU, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (07) :1795-1802